High-grade anal intraepithelial neoplasia among HIV-1-infected men screening for a multicenter clinical trial of a human papillomavirus vaccine

Timothy Wilkin, Jeannette Y. Lee, Shelly Y. Lensing, Elizabeth A. Stier, Stephen E. Goldstone, J. Michael Berry, Naomi Jay, David M. Aboulafia, Mark H. Einstein, Alfred Saah, Ronald T. Mitsuyasu, Joel M. Palefsky

Research output: Contribution to journalArticle

12 Scopus citations

Abstract

Purpose: High-grade anal intraepithelial neoplasia (HGAIN) is the precursor lesion to invasive anal cancer. Human papillomavirus (HPV) vaccination holds great promise for preventing anal cancer. Methods: We examined 235 HIV-1-infected men screening for participation in a multisite clinical trial of a quadrivalent HPV vaccine. All participants had anal swabs obtained for HPV testing and cytology and high-resolution anoscopy with biopsies of visible lesions to assess for HGAIN. Results: HPV types 16 and 18 were detected in 23% and 10%, respectively; abnormal anal cytology was found in 56% and HGAIN in 30%. HGAIN prevalence was significantly higher in those with HPV16 detection compared to those without (38% vs 17%; P =.01). Use of antiretroviral therapy and nadir and current CD4+ cell count were not associated with abnormal anal cytology or HGAIN. Conclusion: HGAIN is highly prevalent in HIV-infected men. Further studies are needed on treatment and prevention of HGAIN.

Original languageEnglish (US)
Pages (from-to)75-79
Number of pages5
JournalHIV Clinical Trials
Volume14
Issue number2
DOIs
StatePublished - Jan 1 2013

    Fingerprint

Keywords

  • HIV-1 infection
  • anal infection
  • anal intraepithelial neoplasia
  • human papillomavirus
  • male

ASJC Scopus subject areas

  • Infectious Diseases
  • Pharmacology (medical)

Cite this

Wilkin, T., Lee, J. Y., Lensing, S. Y., Stier, E. A., Goldstone, S. E., Berry, J. M., Jay, N., Aboulafia, D. M., Einstein, M. H., Saah, A., Mitsuyasu, R. T., & Palefsky, J. M. (2013). High-grade anal intraepithelial neoplasia among HIV-1-infected men screening for a multicenter clinical trial of a human papillomavirus vaccine. HIV Clinical Trials, 14(2), 75-79. https://doi.org/10.1310/hct1402-75